Hypertension--a treatable component of the cardiometabolic syndrome: challenges for the primary care physician.
Patients with the cardiometabolic syndrome (CMS) have an adverse cardiovascular risk factor profile, placing them at increased risk of stroke, coronary artery disease, chronic kidney disease, and type 2 diabetes mellitus. Although no specific treatments for CMS are available per se, prompt recognition and treatment of the individual components of the condition can prevent or delay the development of comorbidities. Primary care physicians are ideally positioned to identify patients with CMS and implement early intervention strategies. Hypertension contributes to many complications of CMS, and rigorous blood pressure control will help to delay or prevent end-organ vascular damage. Achieving blood pressure control to current guideline standards should be eagerly sought in the majority of patients through a combination of lifestyle modifications and appropriate pharmacologic therapy. Antihypertensive drug choice should be personalized, taking into account the CMS determinants present and any compelling indications for specific agents. As an initial approach, a thiazide diuretic is suitable for most cases of uncomplicated hypertension, although many patients will require additional antihypertensives from other classes to achieve their blood pressure goal. It is predicted that, due to the increase in unhealthy lifestyles, the prevalence of CMS will rise in the coming years. Therefore, by meeting the challenge of attaining and maintaining blood pressure control in patients with CMS, primary care physicians have the unique opportunity to markedly improve the health of the nation.
Manrique
Camila M
CM
University of Missouri-Columbia and Harry S. Truman VA Medical Center, Columbia, MO 65212, USA.
Lastra
Guido
G
Palmer
John
J
Stump
Craig S
CS
Sowers
James R
JR
D000419:Albuminuria / Q000517:prevention & control; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000517:prevention & control; D050171:Dyslipidemias; D018149:Glucose Intolerance; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000628:therapy*; D007674:Kidney Diseases / Q000517:prevention & control; D009765:Obesity / Q000150:complications; D011320:Primary Health Care; D040242:Risk Reduction Behavior; D020521:Stroke / Q000517:prevention & control; D013577:Syndrome
D000959:Antihypertensive Agents